US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

219.72 -11.46 (-4.96%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
News headline image
Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Earnings Scheduled For July 31, 2025 ↗
 
Via Benzinga
News headline image
Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday ↗
 
Via Benzinga
News headline image
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 1, 2025 ↗
 
Via Benzinga
News headline image
Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
A Glimpse Into The Expert Outlook On Alnylam Pharmaceuticals Through 10 Analysts ↗
 
Via Benzinga
News headline image
Alnylam Pharma Stock Outlook: Is ALNY Topping Out? ↗
Alnylam Pharma Stock Outlook: For new entrants, chasing the momentum at this point would offer poor risk-reward dynamics. 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Alnylam Pharmaceuticals Through 9 Analysts ↗
 
Via Benzinga
News headline image
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Tesla To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years ↗
 
Via Benzinga
News headline image
What 18 Analyst Ratings Have To Say About Alnylam Pharmaceuticals ↗
 
Via Benzinga
News headline image
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
From Instil Bio
Via GlobeNewswire
News headline image
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case ↗
The Federal Circuit upheld a ruling that Moderna's COVID-19 vaccine does not infringe Alnylam's mRNA patents related to the SM-102 lipid used in Spikevax. 
Via Benzinga
Topics Intellectual Property
News headline image
Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today ↗
Via Benzinga
News headline image
3 High-Flying Stocks That Could Soar Even More ↗
Via The Motley Fool
News headline image
Alnylam Issues 2024 Corporate Responsibility Report
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk ↗
Alnylam analysts highlight Amvuttra's strong launch positioning and limited tariff risk, with bullish ratings maintained despite early launch volatility. 
Via Benzinga
Topics World Trade
News headline image
Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >